Association of brain-derived neurotrophic factor and interleukin-6 serum levels with depressive and anxiety symptoms in hemodialysis patients

Alshogran, Osama Y.; Khalil, Amani A.; Oweis, Ashraf O; Altawalbeh, Shoroq M.; Alqudah, Mohammad

doi:10.1016/j.genhosppsych.2018.04.003

Cited by 29 publications

(21 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is replicated by several studies [76][77][78]. Similarly, findings from a recent report also suggested that circulating IL-6 can be used as a biomarker for prediction of depressive symptoms in HD patients [79]. Another study found a correlation of IL-6 levels with both depression and fatigue in HD patients [80].…”

Section: Il-6 In Physical Diseases Associated With Depressionsupporting

confidence: 57%

See 1 more Smart Citation

Role of Interleukin-6 in Depressive Disorder

Ting

Yang

Tsai

2020

IJMS

248

152

View full text Add to dashboard Cite

Major depressive disorder (MDD), which is a leading psychiatric illness across the world, severely affects quality of life and causes an increased incidence of suicide. Evidence from animal as well as clinical studies have indicated that increased peripheral or central cytokine interleukin-6 (IL-6) levels play an important role in stress reaction and depressive disorder, especially physical disorders comorbid with depression. Increased release of IL-6 in MDD has been found to be a factor associated with MDD prognosis and therapeutic response, and may affect a wide range of depressive symptomatology. However, study results of the IL6 genetic effects in MDD are controversial. Increased IL-6 activity may cause depression through activation of hypothalamic-pituitary-adrenal axis or influence of the neurotransmitter metabolism. The important role of neuroinflammation in MDD pathogenesis has created a new perspective that the combining of blood IL-6 and other depression-related cytokine levels may help to classify MDD biological subtypes, which may allow physicians to identify the optimal treatment for MDD patients. To modulate the IL-6 activity by IL-6-related agents, current antidepressive agents, herb medication, pre-/probiotics or non-pharmacological interventions may hold great promise for the MDD patients with inflammatory features.

show abstract

Section: Il-6 In Physical Diseases Associated With Depressionsupporting

confidence: 57%

“…Hemodialysis Serum IL-6 was higher in patients with depressive symptoms. [79] Hemodialysis A correlation of IL-6 levels was found with both depression and fatigue in hemodialysis patients. [80] Hemodialysis No relationship was found between depression and plasma IL-6 levels.…”

Section: Hemodialysismentioning

confidence: 99%

Role of Interleukin-6 in Depressive Disorder

Ting

Yang

Tsai

2020

IJMS

248

152

View full text Add to dashboard Cite

show abstract

“…Several studies reported that lower serum/plasma BDNF levels were observed in depressed patients, and peripheral BDNF levels were increased after antidepressant treatment 25 . However, the association between serum BDNF levels and depressive or anxiety symptoms in hemodialysis patients is still controversial 26 . In addition, in the present study, the plasma BDNF concentration was not correlated with the J‐PHQ‐9 score.…”

Section: Discussioncontrasting

confidence: 71%

“…In addition, in the present study, the plasma BDNF concentration was not correlated with the J‐PHQ‐9 score. In hemodialysis patients, circulating inflammatory mediators would likely contribute to the development of depressive and anxiety symptoms to a greater extent than BDNF 26 . Reduced plasma level of BDNF is also observed in T2DM 27 and acute coronary syndrome, 28 which are related to systemic or peripheral inflammatory conditions.…”

Section: Discussionmentioning

confidence: 99%

Brain‐derived neurotrophic factor is associated with sarcopenia and frailty in Japanese hemodialysis patients

Miyazaki

Iino²,

Koda³

et al. 2020

Geriatrics Gerontology Int

View full text Add to dashboard Cite

AimWe evaluated several sarcopenia‐related hormones, cytokines and uremic toxins to identify the humoral factors associated with sarcopenia and frailty in Japanese hemodialysis patients.MethodsTwenty Japanese patients aged ≥65 years who underwent maintenance hemodialysis therapy at Uonuma Kikan Hospital for more than 6 months were included in this retrospective cross‐sectional study. Clinical data, including physical function and mental state, were obtained from the clinical records collected during the regular evaluation at the beginning of each hemodialysis therapy session, 3 days after the previous hemodialysis therapy. The diagnosis of sarcopenia and frailty was based on the Asian Working Group for Sarcopenia 2019 and the Japanese version of the Cardiovascular Health Study, respectively. The mental state of patients was evaluated using the Japanese version of the Patient Health Questionnaire 9 (J‐PHQ‐9).ResultsIn univariate analyses, plasma brain‐derived neurotrophic factor (BDNF) levels were significantly lower in patients with severe sarcopenia and frailty. The plasma BDNF concentration was correlated with muscle strength and physical performances, such as the 6‐m walk test, Short Physical Performance Battery and 5‐time chair stand test. BDNF was also correlated with body weight, hemodialysis vintage, and serum levels of total protein and indoxyl sulfate but not with body mass index, appendicular skeletal muscle mass, serum interleukin 6 levels, or J‐PHQ‐9 scores. The odds ratio per 100 pg/mL of BDNF for the prevalence of frailty was 0.353.ConclusionsBDNF is associated with decreased physical performance and the prevalence of severe sarcopenia and frailty in Japanese maintenance hemodialysis patients. Geriatr Gerontol Int 2021; 21: 27–33.

show abstract

“…Patients treated with long‐term haemodialysis are more likely to experience lifestyle changes and increased risks for daily performance, quality of life and psychological disorders (Cukor, Cohen, Peterson, & Kimmel, ). Some previous observational studies showed that depression and anxiety are prevalent among patients on MHD, and are highly correlated with poor health outcomes (Alshogran, Khalil, Oweis, Altawalbeh, & Alqudah, ). Kimmel et al () reported that the prevalence of mental illness in patients on dialysis as 1.5–3.0‐times higher than in patients with other chronic diseases.…”

Section: Discussionmentioning

confidence: 99%

The health‐related quality of life among patients on maintenance haemodialysis: Evaluation using the “EQ‐5D”

Yuan

Yang

Zhang

et al. 2019

Journal of Clinical Nursing

View full text Add to dashboard Cite

Purpose We conducted a cross‐sectional investigation of health‐related quality of life (HRQOL) among maintenance haemodialysis (MHD) patients, and determined important predictive factors of HRQOL in these patients. Methods Psychological factors were evaluated with the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI) and the General Self‐Efficacy Scale (GSES). HRQOL was evaluated with the EQ‐5D. Laboratory data (albumin, haemoglobin and C‐reactive protein) were collected for medical evaluation. We also collected participants’ demographic data, including gender, age, et al. This study was in compliance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist. Results The mean EQ‐5D score was 0.86 ± 0.12, mean HADS‐anxiety score was 5.27 ± 3.41, mean HADS‐depression score was 5.29 ± 3.58, mean PSQI score was 7.00 ± 4.23 and mean GSES score was 6.86 ± 2.03. Participants’ mean haemoglobin was 108.18 ± 16.45 g/L, mean albumin was 41.80 ± 4.61 g/L and mean C‐reactive protein was 8.88 ± 18.50 mg/L. HRQOL was negatively correlated with HADS‐anxiety (r = −0.390, p < 0.001), HADS‐depression (r = −0.385, p < 0.001), PSQI (r = −0.285, p < 0.001) and C‐reactive protein (r = −0.198, p = 0.034). HRQOL was positively correlated with GSES (r = 0.205, p = 0.007). Age (p < 0.001), anxiety (p < 0.001), depression (p = 0.002), and postdialysis unemployment (p < 0.001) were independent risk factors for HRQOL. Conclusion Different health interventions should be implemented to improve patients’ HRQOL. Relevance to clinical practice The results will provide evidence for establishing healthcare interventions to maintain or improve HRQOL among this patient population.

show abstract

Association of brain-derived neurotrophic factor and interleukin-6 serum levels with depressive and anxiety symptoms in hemodialysis patients

Cited by 29 publications

References 45 publications

Role of Interleukin-6 in Depressive Disorder

Role of Interleukin-6 in Depressive Disorder

Brain‐derived neurotrophic factor is associated with sarcopenia and frailty in Japanese hemodialysis patients

The health‐related quality of life among patients on maintenance haemodialysis: Evaluation using the “EQ‐5D”

Contact Info

Product

Resources

About